Sarah Waliany, Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute, shared a post on X:
“Dynamic debate between Julia Rotow and Benjamin Besse on 1L combos vs 1L Osimertinib for EGFR+ NSCLC
- FLAURA2 and MARIPOSA more effective for most subgroups than osi alone: highly important for patients with increased risk features
- Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx).”
More posts featuring Osimertinib.
